Solcia E, Kloppel G, Sobin LH, et al. World Health Organization (WHO) international histological classification of tumors. 2nd ed. Berlin, Germany: Springer 2000.
Travis WD, Brambilla E. Burke, et al World Health Organization (WHO) classification of tumours of the lung, pleura, thymus and heart. 4th ed. Geneva, Switzerland: WHO Press 2015.
Bosman FT, Carneiro F, Hruban RH, et al. World Health Organization (WHO) classification of tumours of the digestive system. 4th ed. Geneva, Switzerland: WHO Press 2010.
Lloyd RV, Osamura RY, Klöppel G, et al. World Health Organization (WHO) classification of tumours of endocrine organs. 4th ed. Geneva, Switzerland: WHO Press 2017.
Raj N, Soumerai T, Valentino E, et al. Next-generation sequencing (NGS) in advanced well differentiated pancreatic neuroendocrine tumors (WD pNETs): A study using MSK-IMPACT J Clin Oncol 2016; 34(suppl): abstr 246..
Bergsland EK, Roy R, Stephens P, et al. Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites. J Clin Oncol 2016.
NCCN Clinical Practice Guidelines in Oncology, Small Cell Lung Cancer (Version 2. 2017), National Comprehensive Cancer Network..
NCCN Clinical Practice Guidelines in Oncology. Non-small Cell Lung Cancer (Version 7 2015). National Comprehensive Cancer Network 2015.
Kunz PL, Catalano PJ, Nimeiri H, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOGACRIN Cancer Research Group (E2211) J Clin Oncol 2018; 36(suppl) abstr 4004.
Morizane C, Machida N, Honma Y, et al. Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system A Japan Clinical Oncology Group study (JCOG1213).) J Clin Oncol 2015; 33(suppl) abstr TPS4143.
Iyer RV, Konda B, Owen DH, et al. Multicenter phase 2 study of nintedanib in patients (pts) with advanced progressing carcinoid tumors J Clin Oncol 2018; 36(suppl) abstr 4105.
Chan JA, Faris JE, Murphy JE, et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). J Clin Oncol 2017; 35(suppl) abstr 228.
Suyama K, Iwase H. Lenvatinib. A promising molecular targeted agent for multiple cancers cancer control 2018; 25 1073274818789361
Castillon JC, Fazio N, Lopez C, et al. Efficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) WHO grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509). Ann Oncol 2018; 29. [suppl]
Pulido EG, Teule A, Alonso-Gordoa T, et al. A phase II trial of palbociclib in metastatic grade 1/2 pancreatic neuroendocrine tumors: The PALBONET study on behalf of the Spanish Taskforce Group of Neuroendocrine Tumors (GETNE). Ann Oncol 2017; 28(Suppl.): 4612-20.
Mehnert JM, Rugo HS, O’Neil BH, et al. Pembrolizumab for patients with PD-L1–positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study. Ann Oncol 2017; 28 [suppl]
Yao JC, Strosberg J, Fazio N, et al. Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). Ann Oncol 2018; 29 [suppl]
Zhang P, Lu M, Li J, Shen L. Efficacy and safety of PD-1 blockade with JS001 in patients with advanced neuroendocrine neoplasms: a non-randomized, open-label, phase 1b trial. Ann Oncol 2018; 29 [suppl]